Pangu
Contact
Clinical Trials
Patients

Skip to content

Company
Our Science
R&D
Patients
Careers
- Working at aTyr
- Career Opportunities
Investors and Media

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

ATYR2810 an Anti-NRP2 Monoclonal Antibody Targets Tumor Associated Macrophages

Society for Immunotherapy of Cancer, 2021

« Immunomodulatory Protein ATYR1923 Disrupts an In-Vitro Model of Sarcoid Granuloma Formation

ATYR2810, a Fully Humanized Monoclonal Antibody Targeting the VEGF-NRP2 Pathway Sensitizes Highly Aggressive and Chemoresistant TNBC Subtypes to Chemotherapy »

© 2007 - 2024 aTyr Pharma. Legal Privacy Policy

By continuing to browse this site, you agree to our use of cookies.

MENU

Company
Our Science
R&D
Patients
Careers
- Career Opportunities
- Working at aTyr
Investors and Media
Privacy Policy